Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01748955 · ClinicalTrials.gov registry record · Phase 4
Paroxetine/Bupropion in Depression With Suicide Attempt or Thoughts: fMRI Study
A Phase 4 study of Depression and Suicidal Ideation, sponsored by New York State Psychiatric Institute.
- Completed
- Registry status
- Phase 4
- Development phase
- 15
- Enrollment target
- 1
- Study location
NCT01748955 is a Phase 4 study of Depression and Suicidal Ideation that has completed, run by New York State Psychiatric Institute. The registered enrollment target is 15 participants, below the 786-participant average among 679 other Depression trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state.
The verdict
NCT01748955, a Phase 4 study of Depression and Suicidal Ideation, has completed, sponsored by New York State Psychiatric Institute.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 15 participants
- Enrollment target
- 1
- Study location
Study Summary
This study uses functional magnetic resonance imaging (fMRI) to investigate the effects of two different antidepressant medications (Paxil CR versus Wellbutrin XL) on reward processing in depressed patients who have attempted suicide or are currently experiencing suicidal thoughts.
Conditions Studied
Interventions
- DRUG Paroxetine CR for Major Depressive Episode
- DRUG Bupropion XL for Major Depressive Episode
Study Locations (1)
New York
- Columbia University/New York State Psychiatric Institute - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2010-06 |
| Est. Completion | 2015-03 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01748955
The ClinicalTrials.gov registry entry for NCT01748955 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 786-participant average among 679 other Depression trials with a reported enrollment target (98% lower). The listed sponsor is New York State Psychiatric Institute, which has 364 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Depression appearing as the primary indexed condition, and to 2 interventions - of which Paroxetine CR for Major Depressive Episode is the first listed.
NCT01748955 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT01748955 about?
NCT01748955 is a clinical study titled "Paroxetine/Bupropion in Depression With Suicide Attempt or Thoughts: fMRI Study". This study uses functional magnetic resonance imaging (fMRI) to investigate the effects of two different antidepressant medications (Paxil CR versus Wellbutrin XL) on reward processing in depressed patients who have attempted suicide or are currently experiencing suicidal thoughts.
What is the current status of trial NCT01748955?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 15 participants. The study started on 2010-06. Estimated completion is 2015-03.
What conditions does trial NCT01748955 study?
This clinical trial studies the following conditions: Depression, Suicidal Ideation.
What interventions are being tested in trial NCT01748955?
The interventions under investigation include: Paroxetine CR for Major Depressive Episode (DRUG), Bupropion XL for Major Depressive Episode (DRUG).
Who is sponsoring clinical trial NCT01748955?
This trial is sponsored by New York State Psychiatric Institute, which has 364 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01748955 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Depression
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Identifying and Treating Depression in the Orthopaedic Trauma Population
RECRUITING · Phase 4
-
Dopaminergic Therapy for Anhedonia - 2
RECRUITING · Phase 4
-
Examining the Effects of Estradiol on Neural and Molecular Response to Reward
RECRUITING · Phase 4
-
Buspirone and Melatonin for Depression Following Traumatic Brain Injury
RECRUITING · Phase 4
-
Processes and Circuitry Underlying Threat Sensitivity as a Treatment Target for Co-morbid Anxiety and Depression
RECRUITING · Phase 4
-
Determining Optimal Treatment Sequences in Anxious Depression (DOTS-AD)
RECRUITING · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.